Invention Grant
- Patent Title: Nucleotide sequence and pharmaceutical composition based thereon with prolonged VEGF transgene expression
-
Application No.: US15819157Application Date: 2017-11-21
-
Publication No.: US10040837B2Publication Date: 2018-08-07
- Inventor: Sergej L'vovich Kiselev
- Applicant: “NEXTGEN” COMPANY LIMITED
- Applicant Address: RU Moscow
- Assignee: “NEXTGEN” COMPANY LIMITED
- Current Assignee: “NEXTGEN” COMPANY LIMITED
- Current Assignee Address: RU Moscow
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: RU2015119768 20150526
- Main IPC: C07K14/475
- IPC: C07K14/475 ; A61K31/00 ; C12N15/67

Abstract:
A nucleic acid or transgene comprising a modified VEGF 3′-untranslated region (3′-UTR) polynucleotide sequence and a polynucleotide sequence encoding a Vascular Endothelial Growth Factor (VEGF). When transformed into a host cell, the nucleic acid or transgene exhibits a high stability and provides prolonged and reliable expression of VEGF. A method for extending the lifetime of transgene mRNA encoding VEGF in a mammalian host cell. A method for treating a subject in need of increased or modified expression of VEGF using this nucleic acid or transgene.
Public/Granted literature
Information query